GlassScriptPhysician profile
Edith M Morgan
NPI 1811976756
$1,957.68
in general payments reported to CMS, 2019-2025
26 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $87.03 · 2024: $660 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.70 |
| Education | $148.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $282.91 | 2023-2025 | Lynparza, Enhertu, Calquence |
| Abbvie INC. | $234.83 | 2024-2025 | |
| Medtronic, INC. | $149.01 | 2025 | Osteocool Rf Ablation System |
| Novartis Pharmaceuticals Corporation | $144.09 | 2024-2025 | |
| Daiichi Sankyo INC. | $133.09 | 2025 | Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $116.62 | 2024-2025 | Libtayo |
| Incyte Corporation | $94.04 | 2024-2025 | Jakafi, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $82.43 | 2023-2024 | Ninlaro, Fruzaqla |
| Sobi, INC | $74.99 | 2024 | |
| Genzyme Corporation | $68.59 | 2025 | |
| Pfizer INC. | $64.09 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.82 | 2025 | |
| Eisai INC. | $60.59 | 2024-2025 | |
| Astellas Pharma US INC | $53.84 | 2024-2025 | Xtandi, Padcev |
| Janssen Biotech, INC. | $46.23 | 2025 | Darzalex, Tecvayli |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $44.09 | 2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $38.43 | 2023 | Padcev, Tukysa |
| Array Biopharma INC | $32.02 | 2025 | Mektovi, Braftovi, Tukysa |
| Gilead Sciences, INC. | $26.36 | 2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $26.20 | 2025 | Xpovio |
| Myriad Genetic Laboratories, INC. | $24.75 | 2024 | Precisetumor |
| Lilly USA, LLC | $24.64 | 2024 | Verzenio, Jaypirca |
| Legend Biotech USA INC. | $19.93 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $19.41 | 2024 | Qinlock |
| Puma Biotechnology, INC. | $17.12 | 2025 | |
| Servier Pharmaceuticals LLC | $16.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.